Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors.

Discovery and optimization of potency and selectivity of a non-Zn-chelating MMP-13 inhibitor with the aid of protein co-crystal structural information is reported. This inhibitor was observed to have a binding mode distinct from previously published MMP-13 inhibitors. Potency and selectivity were improved by extending the hit structure out from the active site into the S1' pocket.

[1]  T. Rush,et al.  Synthesis and SAR of highly selective MMP-13 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[2]  C. Rorabeck,et al.  Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. , 1997, The Journal of clinical investigation.

[3]  B. G. Rao,et al.  Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. , 2005, Current pharmaceutical design.

[4]  J. Pandit,et al.  Potent, selective pyrimidinetrione-based inhibitors of MMP-13. , 2006, Bioorganic & medicinal chemistry letters.

[5]  J. Pelletier,et al.  The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. , 1996, The Journal of clinical investigation.

[6]  J. Woessner,et al.  Matrix metalloproteinases and TIMPs , 2000 .

[7]  A. Parker,et al.  Metalloproteinases: their role in arthritis and potential as therapeutic targets , 2003, Expert opinion on therapeutic targets.

[8]  Michael R Barnes,et al.  Drug discovery in the extracellular matrix. , 2008, Drug discovery today.

[9]  A. Freemont,et al.  In situ zymographic localisation of type II collagen degrading activity in osteoarthritic human articular cartilage , 1999, Annals of the rheumatic diseases.

[10]  K. Geoghegan,et al.  Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. , 1996, The Journal of clinical investigation.

[11]  E. Kaldjian,et al.  Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. , 2003, Arthritis and rheumatism.

[12]  K Ulrich Wendt,et al.  Structural basis for the highly selective inhibition of MMP-13. , 2005, Chemistry and Biology.

[13]  A. Jeng,et al.  The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. , 2004, Current medicinal chemistry.

[14]  T. Cawston,et al.  Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. , 2006, Best practice & research. Clinical rheumatology.

[15]  C. López-Otín,et al.  Cellular Mechanisms for Human Procollagenase-3 (MMP-13) Activation , 1996, The Journal of Biological Chemistry.

[16]  D. Wernicke,et al.  Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis. , 1996, The Journal of rheumatology.

[17]  Bernard Pirard,et al.  Insight into the structural determinants for selective inhibition of matrix metalloproteinases. , 2007, Drug discovery today.

[18]  A. Jeng,et al.  The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. , 2001, Current medicinal chemistry.

[19]  Wang Hui,et al.  Metalloproteases as potential therapeutic targets in arthritis treatment , 2008, Expert opinion on therapeutic targets.